Topics

Predictive Assays Help Personalize Care in Early-Stage HR+ Breast Cancer

11:29 EST 15 Jan 2020 | OncLive

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Original Article: Predictive Assays Help Personalize Care in Early-Stage HR+ Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Predictive Assays Help Personalize Care in Early-Stage HR+ Breast Cancer"

Quick Search

Relevant Topic

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...